Xenon (XENE) has released an update.
Xenon Pharmaceuticals Inc. has strengthened its leadership team by appointing Matthew D. Ronsheim, Ph.D. as the new Chief Operating Officer, poised to lead the company’s strategic and operational initiatives, particularly focusing on the commercial launch of the epilepsy and depression drug azetukalner. With 25 years of experience in the pharmaceutical industry, Ronsheim’s expertise is expected to advance Xenon’s clinical programs and support the company’s growth by managing its portfolio of pre-clinical assets.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
